Rizatriptan 10 mg (n = 181)	Rizatriptan 5 mg (n = 191)	Standard Care (n = 86)
Mean age (y)	42	43	43
% female	91	87	88
% white	98	98	98
% using prophylactics	31	31	28
% using oral contraceptives or hormone replacement	38	39	42
Mean baseline headache severity*	2.4	2.3	2.4
Mean number of attacks treated	19	17	18
Mean number of days in study	167	183	174

*	Baseline severity represents a patients's average baseline severity over all attacks; 2 = moderate, 3 = severe.

Treatment Group	Pain Relief		Pain Free
	vs Standard Care	vs Rizatriptan 5 mg	vs Standard Care	vs Rizatriptan 5 mg
Rizatriptan 10 mg	1.63† (1.14 - 2.34)	1.60‡ (1.23 - 2.08)	1.50* (1.06 - 2.12)	1.93‡ (1.50 - 2.49)
Rizatriptan 5 mg	1.02 (0.72-1.45)	--	0.78 (0.55 - 1.10)	-

*	P < .05.
†	P < .01.
‡	P < .001

Adverse Event	Rizatriptan 10 mg (n = 181)	Rizatriptan 5 mg (n = 191)	Standard Care (n = 86)
Abdominal pain	4%	2%	6%
Asthenia/fatigue	4%	2%†	9%
Back pain	2%	2%*	7%
Dizziness	6%	4%	9%
Headache	3%	2%	6%
Nausea	8%	5%*	13%
Pharyngeal discomfort	1%*	0%†	6%
Somnolence	6%	4%	6%
Upper respiratory infection	7%	4%*	11%
Vomiting	3%	1%*	7%

*	P < .05 vs standard care.
†	P < .01 vs standard care.